The Danish pharmaceutical giant hopes the strategic rebranding and modernising its culture will sharpen the company’s competitive edge in the rapidly evolving obesity and diabetes therapeutics landscape.
Novo Nordisk has activated a major rebrand, shortening its name to ‘Novo’, remaining as Novo Nordisk A/S for its global company name.
Its President and CEO, Mike Doustdar, explained that “healthcare must become more responsive, relevant and easier to fit into everyday life.”
As Novo works to strengthen its competitive edge in the rapidly evolving obesity therapeutics landscape, earlier major strategic changes this year include bolstering of its manufacturing operations, as well as its obesity portfolio through a collaboration agreement.
“healthcare must become more responsive, relevant and easier to fit into everyday life”
Novo President and CEO, Mike Doustdar
In February, Novo agreed a $2.1 billion licensing deal with biotechnology company Vivtex Corporation. The agreement involves developing next-generation oral biologics for obesity and diabetes.
Then in March, Novo expanded its oral GLP-1 manufacturing capacity in Ireland through a near €500 million investment in its obesity and diabetes medicines.
Moreover, last September, freshly appointed Mike Doustdar, shared on LinkedIn that the firm decided on restructuring changes following “increased organisational complexity and costs” associated with the growing competitiveness of the obesity drug landscape.
At the time, Doustdar said the shift “enable us to do two things simultaneously — realign resources toward high-impact R&D and commercial initiatives while creating a more agile organisation that can respond faster to the evolving needs of millions of patients with chronic diseases”.
Meanwhile, the firm has also updated its corporate culture—a change Tania Sabroe, Executive Vice President, People, Organisation & Corporate Affairs, Novo, says “will enable us to move with focus and speed, and our rebrand ensures we show up with relevance and distinctiveness across medicines, partnerships, marketing and stakeholder engagement. Together, these will sharpen our competitive edge and strengthen our role as a trusted partner in healthcare.”
This rebranding of a major pharmaceutical company follows a similar move by J&J Innovative Medicine in September 2023, formerly The Janssen Pharmaceutical Companies of Johnson & Johnson.
A month later, Sandoz, a former division of fellow pharmaceutical firm Novartis, became a standalone company.
No comments yet